102
consecutive patients were analyzed [Median age 66 years (30-82 yrs), male-97(95%), OPX-42(41%), LX-31(30%),
HPX-29(29%). Stages I-2(2%), II-10(10%), III-28 (27%), IVA-47(46%), IVB-15
(15%)]. At RT start, 94 were on oral feeds, 4 on Nasogastric tube (NG) feeds, 3
PEG tube feeds and 1 had jejunostomy. 76 received CTRT, 26 received RT alone. Among the
CTRT group, 58 received concomitant cisplatin-40mg/m2, weekly (46) and 100 mg/m2, three weekly (12), 17
carboplatin and 1 cetuximab. At median follow up (FU) of 25.5 months, mean
overall all survival (OS) for entire cohort was 26 months (SD14.7; range 2-85
months; 1-year: 81.6%, 2-year: 73.6%). Mean OS in oropharyngeal: 25.3 months (1-year:79.3%),
laryngeal: 24.9 months (1-year: 80.1%), and hypopharyngeal: 28 months (1-year: 86.2%). At
last follow up, 52 (51%) were alive, among them 8 (7%) alive with disease; 35
(34%) expired with disease progression and 15 (15%) patients were lost to
follow up. All patients completed RT with 18(17%) having unplanned break. In acute
toxicities, mucositis [grade II-55(54%) and grade III-14(14%)] and dermatitis [grade
II-21(21%), grade III-2(2%)] were common. 24 patients (23.5%) required additional feeding
tube insertion during RT due to dysphagia or prophylactic due to weight loss. At
6 months response evaluation (n=74), 55 (77%) patients had complete response
(CR), 12 (17%) had a residual disease [7 primary alone (1 OPX, 2 LX, 4 HPX), 2 nodal
disease alone, 7 patients had metastasis]. At mean time to recurrence of 9
months, 7 patients (2 OPX, 3 LX, 2 HPX) had recurrence [5 at primary site, 2 nodal].
Four patients had second primary cancers [2 carcinoma lung, 1 carcinoma tongue,
1 carcinoma OPX]. Laryngectomy was done
for 8 patients (6 LX, 1 HPX, 1 OPX with supra-glottic extension); 2 for residual
disease, 3 for dysfunctional larynx, 3 for recurrence.